In the volatile weight loss market, recent events include Altimmune’s soaring stocks and Pfizer encountering setbacks. The European Medicines Agency seeks more data regarding the risk of suicidal tendencies linked to a certain class of medications. AbbVie’s acquisition of ImmunoGen for $10 billion highlights their success with Teliso-V in the advancing field of ADCs. Simultaneously, the FDA delves into cancer concerns related to CAR-T therapies. BioSpace’s experts, Lori Ellis, Greg Slabodkin, and Tyler Patchen, elaborate on these developments.
The weight loss market sees more ups and downs – Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, AbbVie buys ImmunoGen for a cool $10B and scores a win with Teliso-V as ADC momentum continues to build.
Plus, the FDA investigates malignacies linked to CAR-T.
BioSpace’s Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace